Document Detail


Combinations of inhibitors of the renin-angiotensin system with calcium channel blockers for the treatment of hypertension: focus on perindopril/amlodipine.
MedLine Citation:
PMID:  20690889     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Combination antihypertensive therapy with an inhibitor of the renin-angiotensin system (RAS) and a calcium channel blocker (CCB) is a rational approach to achieve blood pressure (BP) goals in patients with hypertension, and may provide additional cardiovascular protection compared to other strategies in special populations. This article reviews the rationale for, and evidence supporting, the use of newer fixed-dose combinations of RAS inhibitors and CCBs, with particular emphasis on perindopril/amlodipine.
METHODS: A literature search was performed in Medline and EMBASE databases to identify articles published up to May 2010 describing the impact of combination treatment with angiotensin receptor blocker (ARB)/CCB or angiotensin-converting enzyme (ACE) inhibitor/CCB based antihypertensive strategies on BP or clinical outcomes.
FINDINGS: A substantial body of evidence supports the BP-lowering efficacy of RAS inhibitor/CCB combination therapy in patients with hypertension. RAS inhibitors and CCBs represent two different and complementary mechanisms of actions; their use in combination is associated with effective BP lowering with favourable tolerability and fewer adverse metabolic effects than some other combination therapies. Currently, intervention studies demonstrating the impact of ARB/CCB combinations on cardiovascular mortality and morbidity are lacking. However, evidence from large outcome trials supports the use of ACE inhibitor/CCB combinations for reducing the risk of cardiovascular and renal events, particularly in high-risk patients. There is also evidence that the benefits of ACE inhibitor/CCB combinations may extend beyond those solely associated with brachial BP lowering, by an additional impact on central BP haemodynamics.
CONCLUSIONS: RAS inhibitor/CCB combination therapy is an effective antihypertensive therapy. Strong evidence supports the antihypertensive efficacy of ACE inhibitor/CCB combinations with cardioprotective and renoprotective properties. In particular, evidence suggests that fixed-dose perindopril/amlodipine effectively decreases BP and currently is the only RAS inhibitor/CCB combination proven to decrease all-cause and cardiovascular mortality as well as major cardiovascular events, and thus is a valuable option for the management of hypertension, especially in high-risk patients.
Authors:
Jean-Jacques Mourad; Sylvain Le Jeune; Anthony Pirollo; Clarisse Mourad; Yann Gaudouen; Marilucy Lopez-Sublet
Related Documents :
11720109 - What do international guidelines say about therapy?
17722969 - Benefit-risk assessment of nesiritide in the treatment of acute decompensated heart fai...
23073689 - Influence of carbon dioxide insufflation of the neck on intraocular pressure during rob...
2283649 - The role of ace inhibitors in the management of hypertension.
10431429 - Outcomes from treatment. clinical applications from recent trials.
16609299 - Which drug should be used to treat patients with uncomplicated essential hypertension?
7059029 - Effect of altered resistive load on left ventricular systolic mechanics in dogs.
2432009 - Effects of diltiazem on cation transport across erythrocyte membranes of hypertensive h...
1753239 - Sympathetic vascular function in patients with central dysautonomia.
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Current medical research and opinion     Volume:  26     ISSN:  1473-4877     ISO Abbreviation:  Curr Med Res Opin     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-08-16     Completed Date:  2010-12-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  England    
Other Details:
Languages:  eng     Pagination:  2263-76     Citation Subset:  IM    
Affiliation:
Dept of Internal Medicine & Arterial Hypertension, Avicenne Hospital, Bobigny Cedex, France. jean-jacques.mourad@avc.aphp.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amlodipine / administration & dosage*,  adverse effects
Angiotensin-Converting Enzyme Inhibitors / administration & dosage,  adverse effects
Antihypertensive Agents / administration & dosage,  adverse effects
Calcium Channel Blockers / administration & dosage*,  adverse effects
Drug Therapy, Combination
Humans
Hypertension / drug therapy*,  physiopathology
Perindopril / administration & dosage*,  adverse effects
Renin-Angiotensin System / drug effects,  physiology
Treatment Outcome
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Calcium Channel Blockers; 82834-16-0/Perindopril; 88150-42-9/Amlodipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Emerging drugs for high-grade osteosarcoma.
Next Document:  Effects of long-term non-invasive home mechanical ventilation on chronic respiratory failure.